EcoDrugPlus

Proteasome Subunit Alpha Type-1

Ensembl ID : ENSPNAG00000016466
Gene Symbol: LOC108439060
3 Cross references
269 Possible Orthologues:

Proteasome Subunit Alpha Type-1

Ensembl ID : ENSPNAG00000016701
Gene Symbol: LOC108439057
3 Cross references
269 Possible Orthologues:

Proteasome Subunit Alpha Type-2

Ensembl ID : ENSPNAG00000008730
Gene Symbol: LOC108425697
3 Cross references
269 Possible Orthologues:

Proteasome Subunit Alpha Type-2-Like

Ensembl ID : ENSPNAG00000015282
Gene Symbol: LOC108440756
2 Cross references
269 Possible Orthologues:

Proteasome Subunit Alpha Type-6-Like

Ensembl ID : ENSPNAG00000007814
Gene Symbol: LOC108443807
3 Cross references
278 Possible Orthologues:

Proteasome Subunit Alpha Type-7

Ensembl ID : ENSPNAG00000027550
Gene Symbol: LOC108416288
3 Cross references
183 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSPNAG00000021917
Gene Symbol: PSMB11
3 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSPNAG00000026338
Gene Symbol: LOC108435551
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSPNAG00000021948
Gene Symbol: LOC108438927
3 Cross references
208 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSPNAG00000025687
Gene Symbol: LOC108410945
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSPNAG00000028980
Gene Symbol: LOC108415718
3 Cross references
217 Possible Orthologues:

Proteasome Subunit Beta Type-9-Like

Ensembl ID : ENSPNAG00000010735
Gene Symbol: LOC108433730
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).